Compare

BlossomHill Therapeutics/$BLSM

1D1W1M3M6MYTD1Y5YMAX

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
Ticker
$BLSM
Sector
Health
Primary listing
NASDAQ
Employees
69
Headquarters
San Diego, United States
Website
bhtherapeutics.com

BLSM Metrics

BasicAdvanced
$512M
-
-$31.83
-
-

What the Analysts think about BLSM

Analyst ratings (Buy, Hold, Sell) for BlossomHill Therapeutics stock.
Analyst projections of the future price of BlossomHill Therapeutics stock.

Bulls say / Bears say

In the difficult-to-treat EGFR C797S lung-cancer subgroup, BH-30643 produced a 45% objective response rate and an 88% disease-control rate in interim data; the company also reported low rates of dose reduction or discontinuation and FDA Fast Track status. (BlossomHill Therapeutics)
BH-30236 has shown early activity in relapsed or refractory AML and higher-risk MDS, including in patients previously treated with venetoclax: 53% of evaluable patients in the combination cohort had at least a 50% reduction in bone-marrow blasts, and one achieved an MRD-negative remission. The company reported that treatment was generally well tolerated. (BlossomHill Therapeutics)
The preclinical BH-501284 programme could broaden the pipeline beyond the two clinical-stage assets: the company reported prolonged KRAS target engagement and tumour regression across several KRAS-mutant animal models. It is targeting an IND submission in the first quarter of 2027. (BlossomHill Therapeutics)
BH-30643’s headline response data are still preliminary: they cover 40 C797S-positive patients, include two unconfirmed responses and have a median follow-up of 6.9 months. The response rate and durability therefore still need confirmation in later-stage testing. (BlossomHill Therapeutics)
BH-30236 remains in first-in-human dose escalation, and its reported AML/MDS activity is based on small evaluable groups and a reduction in bone-marrow blasts, not established clinical benefit. The early results may not translate into durable responses or later-stage success. (BlossomHill Therapeutics)
BlossomHill has no product-sales revenue and continues to incur substantial losses; it used $44.2 million in operating cash in the first half of 2026. Despite IPO proceeds, management’s cash forecast reaches only into the second quarter of 2028, leaving further development dependent on execution and potentially additional financing. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.

BLSM Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

BLSM Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.